PatientsVille.com Logo

CONDITION AGGRAVATED and Ativan

PatientsVille

CONDITION AGGRAVATED Symptoms and Causes

Parkinson's disease (PD) is a type of movement disorder. It happens when nerve cells in the brain don't produce enough of a brain chemical called dopamine. Sometimes it is genetic, but most cases do not seem to run in families. Exposure to chemicals in the environment might play a role.

Symptoms begin gradually, often on one side of the body. Later they affect both sides. They include

  • Trembling of hands, arms, legs, jaw and face
  • Stiffness of the arms, legs and trunk
  • Slowness of movement
  • Poor balance and coordination

As symptoms get worse, people with the disease may have trouble walking, talking, or doing simple tasks. They may also have problems such as depression, sleep problems, or trouble chewing, swallowing, or speaking.

There is no lab test for PD, so it can be difficult to diagnose. Doctors use a medical history and a neurological examination to diagnose it.

PD usually begins around age 60, but it can start earlier. It is more common in men than in women. There is no cure for PD. A variety of medicines sometimes help symptoms dramatically. Surgery and deep brain stimulation (DBS) can help severe cases. With DBS, electrodes are surgically implanted in the brain. They send electrical pulses to stimulate the parts of the brain that control movement.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for CONDITION AGGRAVATED

CONDITION AGGRAVATED treatment research studies

Ativan clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ativan Side Effects

Anxiety (68)
Pain (51)
Insomnia (44)
Depression (42)
Confusional State (41)
Dyspnoea (36)
Nausea (36)
Headache (36)
Somnolence (34)
Fatigue (34)
Asthenia (32)
Feeling Abnormal (30)
Amnesia (30)
Dizziness (29)
Agitation (28)
Diarrhoea (27)
Hallucination (25)
Loss Of Consciousness (23)
Death (23)
Convulsion (22)
Aggression (22)
Fall (21)
Vomiting (21)
Overdose (21)
Tremor (20)
Pneumonia (20)
Condition Aggravated (20)
Hypotension (20)
Pulmonary Embolism (18)
Depressed Level Of Consciousness (17)
Rash (17)
Dehydration (17)
Coma (17)
Decreased Appetite (16)
Abdominal Pain (16)
Malaise (16)
Mental Status Changes (16)
Constipation (15)
Palpitations (14)
Disorientation (14)
Injury (14)
Pyrexia (13)
Nervousness (13)
Tachycardia (13)
Vision Blurred (13)
Emotional Distress (12)
Deep Vein Thrombosis (12)
Pruritus (12)
Urinary Tract Infection (12)
Pain In Extremity (12)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Does valium cause afib?

I hade bacterial prostatit and i used too many antibiotik but not help but when i used alprazolam or ativan sudenly i became okai but problem is i dident find ativan in ukraine and my sister always send to me ativan frome canada some body plea

I took this for 3 weeks and by the end of my treatment I wanted to shoot everyone in my home, myself included.

I was having bad dreams and anxiety attacks (My Mom was murdered in 2005). I started drinking to calm my nerves, but decided to quit alcohol. I was told by a nurse that quiting 'Cold Turkey' could be dangerous, so I went to see th

My email is skynet.ukr@ukr.net

My mother in law has been taking ativan 4 times a day , every since then she has fallen and broke her nose twice in less than four mths apart,effected her eye sight,confussion,disorented,cant remember anything are anybody. They need to take this crap

What I have been exsperiencing is when I want to go to sleep I start having vivid confusing images that don't make sense. I will be thinking about my day then a thought like eating ice cream and cake will pop in my mind and I never ate ice

I have been prescribed Methicol Mecobalamin 500mg twice a day for a condition diagnosed as forzen shoulder with off-and -on pains to be taken for a month. What could be the side effects of this medication.

When I 1st took Levothyroxine it made me very, very anxious. My anxiety seemed to get a little better, after my Dr found that I needed 112 mg for my condition. I have been taking it for about 2 years, but in the last 6 months my anxiety is back, and

My grand father was diagnosed with dementiaalzheimer's type and was prescribed Aricept. After he started taking Aricept, his condition have gotten worse and he actually died yesterday. He was 83 years old.

4-5 hours after venofer infusion developed fever 100 F ,pulse 120/min,palpatation and bronchospasm.i took ventolin inhaler but was of no use i remained in that condition for 3 more hours when brochospasm was not relieved and worsened i went to emerge

45 Male on Enbrel 4 + years , My condition is all but gone and I really use no other meds now. Expect a dry cough , Poor night vision ,Memory loss ,and in some cases (345) amniesia. IHAVE noticed a difficulty in learning new&am

A septocaine injection for a lower mandibular block has pretty much destroyed my life. I have gone through 3 years of pain and drugs knowing now this is a condition I must endure the rest of my life. Had I a clue the dentist was injecting me with suc

After having a routine dcr with a local anaeasthesia Lignospan adminstered. P atient suffered from extreme vertigo. Treated with oxygen. Condition subsided after 8 hours

Apart from my few issues i hope this will help my condition and i trust my doctor i have had two infusions and i believe i need only one more i am 61 years of age and hope this is the case. Feed back would be wonderful

Bronchial asthma condition ketotifen whether use r not

Carol, I took Avelox for 10 days, then had a fever for 3 days, horrible red rash all over the body and severe headache and swelling of the wrists, hands and fingers. Sounds like the same condition as yours. I have read many posts and you are the m

CONDITION AGGRAVATED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)
Condition: Healthy Subjects
Interventions: Drug: Lorazepam;   Drug: Placebo
Outcome Measures: Correlated Brain Activity using MEG and SNI analysis;   Correlated Brain Activity using MEG and standard analyses
2 Unknown  Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy
Condition: Patient Satisfaction for Bronchoscopy
Interventions: Drug: Lorazepam;   Drug: Control
Outcome Measures: patient satisfaction;   relationship between patient satisfaction and sleep quality, anxiety level
3 Unknown  IM Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Agitation
Interventions: Drug: IM olanzapine;   Drug: haloperidol plus lorazepam IM
Outcome Measures: Positive and Negative Symptom Scale Excited Component (PANSS-EC);   Agitation-Calmness Evaluation Scale (ACES)
4 Recruiting Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Lorazepam;   Drug: Placebo;   Drug: Haloperidol decanoate;   Behavioral: Questionnaires
Outcome Measure: Control of Delirium Symptoms
5 Recruiting The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
Condition: Alzheimer's Disease (AD)
Intervention: Drug: lorazepam
Outcome Measures: AVLT Long term memory score;   Groton Maze Learning Test (GMLT) score
6 Recruiting Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
Conditions: Status Epilepticus;   Epilepsy
Interventions: Drug: Clonazepam;   Drug: Fosphenytoin;   Drug: Placebo;   Drug: Lorazepam
Outcome Measures: Percentage of patient with a cessation of seizures and absence of recurrence;   Duration between the first cessation and the recurrence of seizures;   Percentage of patients having had a second injection of benzodiazepine;   Percentage of patients having had an injection of the second line treatment;   Percentage of patients having a general anesthesia for refractory status epilepticus;   Percentage of patients having had a side effect;   Percentage of patients having been mechanically ventilated;   Glasgow Coma Scale;   Mortality;   Length of stay in Intensive Care Unit;   Length of stay in hospital
7 Not yet recruiting Clobazam Use in Epilepsia Partialis Continua - Pilot Study
Conditions: Epilepsia Partialis Continua;   Kojewnikov's Epilepsy;   Epilepsy
Interventions: Drug: Clobazam;   Drug: Clonazepam;   Drug: Lorazepam
Outcome Measures: Time (measured in minutes) to onset of seizure freedom;   Reduction of seizure frequency/minute;   Mental status preservation off sedating anticonvulsants as measured by the MoCA© scale;   Ambulatory function as measured by the Hauser Ambulation Index
8 Recruiting Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly
Condition: Healthy Volunteers
Interventions: Drug: etifoxine;   Drug: lorazepam;   Drug: Placebo
Outcome Measure: Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)
9 Recruiting Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in Elderly
Condition: Volunteers Aged Between 65 and 75 Years Old
Interventions: Drug: etifoxine;   Drug: Lorazepam;   Drug: Placebo
Outcome Measure: Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)
10 Recruiting Characterizing and Predicting Drug Effects on Cognition
Condition: Cognitive Deficits
Interventions: Drug: Topiramate;   Drug: Lorazepam
Outcome Measures: Relationship between neurocognitive performance and study drug plasma concentration;   Neurophysiological effect of study drug on working memory
11 Recruiting Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD)
Conditions: Liver Fibrosis;   Alpha-1 Antitrypsin Deficiency;   AAT Deficiency;   AATD
Interventions: Device: Abdominal ultrasound;   Procedure: History and physical;   Procedure: Intravenous catheter;   Procedure: Blood draw;   Other: Liver questionnaire;   Procedure: Liver Biopsy;   Drug: Midazolam;   Drug: Fentanyl;   Drug: Lidocaine;   Drug: Acetaminophen;   Drug: Lorazepam;   Drug: Oxycodone/Acetaminophen;   Drug: Ondansetron
Outcome Measures: To estimate the prevalence and histologic spectrum of liver injury in an adult with Alpha-1 Antitrypsin deficiency and a genotype of ZZ.;   To identify environmental and host risk factors for clinically significant liver fibrosis.;   To define the diagnostic accuracy of non-invasive markers of fibrosis in AAT liver disease.;   To explore epigenetic markers for the development of liver fibrosis.;   To quantify liver fibrosis progression.
12 Recruiting Sedative Premedication: Efficacy On Patient Experience
Condition: Perioperative Anxiety
Interventions: Drug: Lorazepam;   Other: no premedication;   Drug: Placebo (microcrystalline celluloses)
Outcome Measures: the EVAN score;   the perioperative level of anxiety
13 Not yet recruiting Explanation About Sleep in Post Trauma Patients
Conditions: Post Traumatic Stress Disorder;   Sleep Deprivation
Interventions: Behavioral: Explanation encouraging sleep;   Behavioral: Explanation discouraging sleep;   Drug: Lorazepam
Outcome Measure: PTSD severity as measured by CAPS
14 Recruiting Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability
Condition: Dental Care for Disabled
Interventions: Drug: Midazolam Mylan;   Drug: Lorazepam Mylan;   Drug: Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
Outcome Measures: Level of cooperation of patient when receiving regular dental care;   Recording of vital parameters during regular dental care delivery;   Level of patient comfort and possible side-effects after dental treatment session
15 Recruiting A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865
Condition: Healthy
Interventions: Drug: PF-06372865 or Placebo;   Drug: PF-06372865 or Placebo or Lorazepam
Outcome Measures: Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Area Under the Curve From Time Zero to Extrapolated Infinite Time;   Apparent Oral Clearance (CL/F);   Apparent Volume of Distribution (Vz/F);   Plasma Decay Half-Life (t1/2);   Area Under the Curve From Time Zero to 24 hours;   Change in Saccadic Eye Movements (saccadic reaction time, saccadic peak velocity and saccadic inaccuracy);   Change in Body Sway;   Change in Smooth Pursuit;   Change in Bond and Lader VAS;   Change in Adaptive Tracking;   Change in Visual Verbal Learning Test;   Change in Pharmaco-EEG
16 Unknown  Enteral Versus Intravenous Sedation in Critically Ill High-risk ICU Patients
Conditions: Critical Illness;   Mechanical Ventilation Complication
Interventions: Procedure: Enteral Sedation (EN);   Procedure: Control group: Intravenous Sedation (IV)
Outcome Measures: Percent of efficacy, measured by observed RASS = desired RASS ± 1.;   Sedation protocol effectiveness: percentage of "protocol violation days" on the total of ICU days.;   Delirium and coma free days (respectively negative CAM-ICU and RASS > - 3 in all daily observations until 28° ICU day) (11);   Ventilation free days (12);   Nursing evaluation of sedation adequacy (communication skills, cooperation, environment tolerance) (13);   Overall ICU and hospital mortality, absolute mortality after 1 year from ICU discharge.;   Sedative drugs costs.;   Indirect inefficacy markers
17 Recruiting Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Conditions: Alcohol Withdrawal Delirium;   Alcohol Withdrawal Associated Autonomic Hyperactivity;   Alcohol Withdrawal Hallucinosis;   Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Drug: Dexmedetomidine;   Drug: Placebo
Outcome Measures: The length of ICU stay defined as the time between randomization and ICU transfer orders.;   The number of delirium-free and ventilator-free days during the first 28 days of hospitalization;   The length in days of the hospital stay;   Scores at hospital discharge on the Mini Mental Exam, Beck Depression Inventory, Beck Anxiety Inventory and PTSD checklist.;   Resource utilization costs associated with this hospitalization.;   Predefined adverse events;   average MINDS score
18 Unknown  Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
Condition: Depression
Interventions: Device: Thrymatron System IV device (CONSOLIDATION ELECTROCONVUsLIVE THERAPY) plus PHARMACOTHERAPY;   Drug: PHARMACOTHERAPY
Outcome Measures: Hamilton Depression Rating Scale 21 items (HDRS-21);   Mini-Mental State Examination (MMSE 35);   UKU - Adverse effects rating scales;   Demographical Data Memory (MEDABI-20);   Rey Figure;   Trail Making Test A;   Trail Making Test B;   Stroop Test;   Direct and inverse digits (WAIS, Weschler Adults Intelligence Sacle).;   Vocabulary WAIS (Weschler Adults Intelligence Scale);   Frequency Hospitalization Quotient;   Hospital Day Quotient (HDQ)
19 Not yet recruiting Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
Outcome Measures: Complete Response, Acute Phase (Day 1), Cycle 1;   Complete Response, Delayed Phase (Days 2 to 11), Cycle 1;   Complete Response - Cycle 2 and beyond;   No Significant Nausea - Cycle 2 and beyond;   Failure of standard anti-emetic prophylaxis, Day 1 to Day 11, Cycle 1 and beyond;   Frequency of common adverse events associated with anti-emetics;   Severity of common adverse events associated with anti-emetics
20 Recruiting TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation
Conditions: Cardiac Arrest;   Postanoxic Encephalopathy;   Status Epilepticus
Interventions: Drug: Anti-epileptic drugs;   Other: No anti-epileptic drugs
Outcome Measures: Neurological outcome;   Long term outcome